PHILIPPINE Reclamation Authority (PRA) Chairman Alexander Lopez said there were plans to build a monorail connecting Taft Avenue and SM Mall of Asia (MOA) in Pasay City with the first phase covering 1 ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell ...

(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...

The trial compared the ADC patritumab deruxtecan to chemotherapy in people with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC) after the failure of a third ...

NZ Breast Cancer Foundation: New Breast Cancer Wonder Drug Would Be Life-Changing For NZ Women Breast Cancer Foundation NZ ...

Data from the TROPION-Lung02 reported at the World Congress on Lung Cancer (WCLC) showed an overall response rate of 37% when DS-1062 (datopotamab deruxtecan) was combined with Merck & Co's PD-1 ...

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer – in one of the most ...

The HERTHENA-Lung02 Phase III trial of patritumab deruxtecan, in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase ...

Patritumab deruxtecan’s safety profile in the trial was consistent with what had been established in prior studies, with no new signals, according to the companies. “The majority of interstitial lung ...